Trials / Conditions / Beta Thalassemia Intermedia
Beta Thalassemia Intermedia
6 registered clinical trials studyying Beta Thalassemia Intermedia — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Enrolling By Invitation | The BENeFiTS Trial in Beta Thalassemia Intermedia NCT04432623 | Phoenicia BioScience | Phase 1 / Phase 2 |
| Terminated | Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (F NCT04059406 | Ionis Pharmaceuticals, Inc. | Phase 2 |
| Completed | ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19 NCT06831799 | Hospital Universitari Vall d'Hebron Research Institute | — |
| Terminated | Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia. NCT01571635 | Celgene | Phase 2 |
| Completed | Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon NCT01642758 | Boston University | Phase 2 |
| Completed | Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand NCT01609595 | Boston University | Phase 2 |